Research Radar Ep. 1: Payments, Peptides & Proper Testing

Snippet

Body

View this post on the web at https://derekpruski.substack.com/p/research-radar-ep-1-payments-peptides

Topic 1: Payment processing in the research space
One of the most persistent behind-the-scenes headaches for research companies right now is payment processing. Vendors have been cycling through as many as seven different processors trying to find one that’s both reliable and will actually pay out. The result: customers hitting declined transactions at checkout, often with no clear explanation.
This isn’t a solvency issue — it’s a risk classification problem. Research-space companies are routinely flagged by processors even when operating within legal bounds. Until the industry finds a more stable processing solution, expect occasional friction at checkout across multiple vendors.
Topic 2: Testing standards — what they mean and why they matter
We broke down the full testing stack that separates accountable vendors from the rest:
Identification — confirms the compound is what the label says it is
Net content — verifies the total amount of compound in the vial
Net purity — checks what percentage of that content is actually the target peptide
Endotoxins — screens for bacterial byproducts that can cause serious immune reactions
Sterility — confirms the product is free of viable microorganisms
Heavy metals — tests for contamination from lead, arsenic, cadmium, and similar
USP 61 vs USP 71 — not the same test
USP 61 is a 5-day bioburden test. It counts the number of living microorganisms present but does not confirm sterility. It gives a microbial load reading, not a pass/fail on sterility.
USP 71 is a 14-day sterility test and the gold standard. It determines whether the product is free of viable microorganisms. This is what you want to see on a COA for injectable research compounds.
A vendor citing USP 61 for “sterility” is technically passing a bioburden test — not a sterility test. These are not interchangeable.
Topic 3: New product formats entering the research space
The product landscape is expanding beyond reconstituted vials. Nasal sprays and capsules are now showing up with third-party testing — specifically net content verification — which is something we haven’t seen applied to these formats before.
This is a meaningful development. Holding alternative delivery formats to the same documentation standards as injectables raises the bar across the board and gives researchers more confidence when evaluating non-injectable options.
Listener Q&A: RFK and the category 1 vs category 2 peptide reclassification
Rick walked us through the regulatory background on RFK’s proposed reclassification of certain peptides — specifically the distinction between category 1 and category 2 compounds and what a shift between those categories means for the research landscape.
Category 2 peptides are those with stronger evidence of clinical or therapeutic potential — the tier that’s drawn more regulatory scrutiny. Movement into or out of category 1 affects compounding access, research availability, and how vendors are able to operate. Rick broke down the mechanics of how that reclassification process works under the RFK proposals and what it could mean going forward.
All products discussed are for research use only and not intended for human consumption.

Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXNraS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSWpveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVNekF6TkRFd09Td2lhV0YwSWpveE56YzFNakkyTURBMExDSmxlSEFpT2pFNE1EWTNOakl3TURRc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lpd2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5LkVESFY1VFRUZ1RYZXZMZWRiOS1kY1VKeldPU1JTYlVob0Y0U3dsQkNQdmsiLCJwIjoxOTMwMzQxMDksInMiOjMzNjUzNjcsImYiOnRydWUsInUiOjI3MzYyMjM5OCwiaWF0IjoxNzc1MjI2MDA0LCJleHAiOjIwOTA4MDIwMDQsImlzcyI6InB1Yi0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.ArXT81X36aKmUuUi4MWz9fggI7rHezX82p4RVf5jpT4?